Longeveron Inc. (LGVN)
| Market Cap | 7.33M-74.1% |
| Revenue (ttm) | n/a-42.7% |
| Net Income | n/a-26.6% |
| EPS | n/a+21.1% |
| Shares Out | 3.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,833 |
| Open | 2.45 |
| Previous Close | 2.44 |
| Day's Range | 2.38 - 2.57 |
| 52-Week Range | 2.30 - 12.30 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 10.00(+314.94%) |
| Earnings Date | n/a |
Insiders here have filed 17 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
$LGVN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in LGVN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LGVN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LGVN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LGVN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| R&D costs | $3.19M | 33.91% |
| G&A costs | $3.16M | 33.54% |
| Personnel costs | $3.06M | 32.54% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LGVN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LGVN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LGVN
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $252.93K |
| VTIVanguard Morningstar Total Stock Market ETF | $249.30K |
Estimated from each fund’s disclosed top holdings × AUM
LGVN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LGVN’s recent data — informational, not investment advice